Provided by Tiger Fintech (Singapore) Pte. Ltd.

GlycoMimetics

15.70
0.0000
Volume:- -
Turnover:171.19K
Market Cap:1.01B
PE:-34.34
High:15.70
Open:15.70
Low:15.70
Close:15.70
52wk High:63.00
52wk Low:14.06
Shares:64.53M
Float Shares:42.78M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4572
EPS(LYR):-0.5875
ROE:-182.66%
ROA:-73.99%
PB:300.17
PE(LYR):-26.72

Loading ...

Company Profile

Company Name:
GlycoMimetics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.